DK3290404T3 - 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrilderivater som intermediater til fremstillingen af [(5-(halophenyl)-3-hydroxypyridin-2-carbonyl)-amino]alkansyrederivater - Google Patents

5-((halophenyl)-3-halo-pyridin-2-yl)-nitrilderivater som intermediater til fremstillingen af [(5-(halophenyl)-3-hydroxypyridin-2-carbonyl)-amino]alkansyrederivater Download PDF

Info

Publication number
DK3290404T3
DK3290404T3 DK17191362.7T DK17191362T DK3290404T3 DK 3290404 T3 DK3290404 T3 DK 3290404T3 DK 17191362 T DK17191362 T DK 17191362T DK 3290404 T3 DK3290404 T3 DK 3290404T3
Authority
DK
Denmark
Prior art keywords
halophenyl
nitril
hydroxypyridine
pyridin
intermediates
Prior art date
Application number
DK17191362.7T
Other languages
Danish (da)
English (en)
Inventor
Christopher M Lanthier
Boris Gorin
Jan Oudenes
Craig Edward Dixon
Alan Qingbo Lu
James Densmore Copp
John Michael Janusz
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Application granted granted Critical
Publication of DK3290404T3 publication Critical patent/DK3290404T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
DK17191362.7T 2011-06-06 2012-06-05 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrilderivater som intermediater til fremstillingen af [(5-(halophenyl)-3-hydroxypyridin-2-carbonyl)-amino]alkansyrederivater DK3290404T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06
EP15189822.8A EP3000808B1 (en) 2011-06-06 2012-06-05 5-((halophenyl)-3-hydroxy-pyridin-2-yl)-carboxylic acid derivatives as intermediates for the preparation of carbonylamino alkanoic acids, esters and amides thereof

Publications (1)

Publication Number Publication Date
DK3290404T3 true DK3290404T3 (da) 2020-02-17

Family

ID=47262177

Family Applications (4)

Application Number Title Priority Date Filing Date
DK17191362.7T DK3290404T3 (da) 2011-06-06 2012-06-05 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrilderivater som intermediater til fremstillingen af [(5-(halophenyl)-3-hydroxypyridin-2-carbonyl)-amino]alkansyrederivater
DK12796374.2T DK2718265T3 (en) 2011-06-06 2012-06-05 Process for the preparation of [(3-Hydroxypyridine-2-carbonyl) amino] alkanoic acids, esters and amides
DK19214405.3T DK3683209T3 (da) 2011-06-06 2012-06-05 Fremgangsmåde til fremstilling af [(5-(3-chlorphenyl)-3-hydroxypyridin-2-carbonyl)-amino]eddikesyre fra 5-((3-chlorphenyl)-3-chlor-pyridin-2-yl)-nitril og fremgangsmåde til fremstilling af 5-((halogenphenyl)-3-halogen-pyridin-2-yl)-nitrilderivater
DK15189822.8T DK3000808T3 (da) 2011-06-06 2012-06-05 5-((halophenyl)-3-hydroxy-pyridin-2-yl)-carboxylsyre-derivater som intermediater til fremstillingen af carbonylamino-alkansyrer, estere og amider deraf

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK12796374.2T DK2718265T3 (en) 2011-06-06 2012-06-05 Process for the preparation of [(3-Hydroxypyridine-2-carbonyl) amino] alkanoic acids, esters and amides
DK19214405.3T DK3683209T3 (da) 2011-06-06 2012-06-05 Fremgangsmåde til fremstilling af [(5-(3-chlorphenyl)-3-hydroxypyridin-2-carbonyl)-amino]eddikesyre fra 5-((3-chlorphenyl)-3-chlor-pyridin-2-yl)-nitril og fremgangsmåde til fremstilling af 5-((halogenphenyl)-3-halogen-pyridin-2-yl)-nitrilderivater
DK15189822.8T DK3000808T3 (da) 2011-06-06 2012-06-05 5-((halophenyl)-3-hydroxy-pyridin-2-yl)-carboxylsyre-derivater som intermediater til fremstillingen af carbonylamino-alkansyrer, estere og amider deraf

Country Status (23)

Country Link
US (6) US9145366B2 (OSRAM)
EP (5) EP4026829A1 (OSRAM)
JP (6) JP6290781B2 (OSRAM)
KR (5) KR102171315B1 (OSRAM)
CN (1) CN106518759B (OSRAM)
AU (4) AU2012268426B2 (OSRAM)
CA (2) CA2838194C (OSRAM)
CY (4) CY1117177T1 (OSRAM)
DK (4) DK3290404T3 (OSRAM)
ES (4) ES2647602T3 (OSRAM)
HR (4) HRP20211916T1 (OSRAM)
HU (4) HUE057571T2 (OSRAM)
IL (1) IL229775A (OSRAM)
LT (3) LT3683209T (OSRAM)
MX (2) MX347709B (OSRAM)
NO (1) NO2686520T3 (OSRAM)
PL (4) PL3000808T3 (OSRAM)
PT (4) PT3000808T (OSRAM)
RS (3) RS56580B1 (OSRAM)
RU (2) RU2764667C2 (OSRAM)
SI (4) SI3000808T1 (OSRAM)
SM (3) SMT202000061T1 (OSRAM)
WO (1) WO2012170377A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2922078T3 (es) 2006-06-26 2022-09-07 Akebia Therapeutics Inc Inhibidores de prolil hidroxilasa y métodos de uso
NO2686520T3 (OSRAM) * 2011-06-06 2018-03-17
KR102461176B1 (ko) * 2013-06-13 2022-11-01 아케비아 테라퓨틱스 인코포레이티드 빈혈 치료용 조성물 및 치료방법
CR20160222U (es) * 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CN105384687B (zh) 2014-09-02 2018-05-01 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) * 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
JP2020500925A (ja) * 2016-12-13 2020-01-16 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の新規結晶形及びその製造方法
IL269623B2 (en) * 2017-03-29 2025-05-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
AU2019265629B2 (en) * 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
CN113767089B (zh) * 2019-04-26 2024-06-11 株式会社钟化 伐度司他中间体的制造方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
US20230159462A1 (en) * 2019-12-10 2023-05-25 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
EP4094832A4 (en) 2020-01-24 2024-04-17 APS Japan Co., Ltd. Photocatalyst unit and mask provided with photocatalyst unit
WO2022006427A1 (en) * 2020-07-02 2022-01-06 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2023111990A1 (en) 2021-12-17 2023-06-22 Akebia Therapeutics, Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
WO2024165507A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Use of hif-1α stabilizing agents for the treatment of type i interferonopathies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (OSRAM) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59401923D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
AU5762896A (en) 1996-04-30 1997-11-19 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
HUP0101482A3 (en) 1998-03-23 2002-12-28 Aventis Pharm Prod Inc Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US20030153503A1 (en) 2001-12-06 2003-08-14 Klaus Stephen J. Methods of increasing endogenous erythropoietin (EPO)
NZ536908A (en) 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
IL166426A0 (en) * 2002-08-29 2006-01-15 Merck & Co Inc N-biarylmethyl aminocycloalkanecarboxamide derivatives
DE60330587D1 (de) 2002-10-16 2010-01-28 Isis Innovation Screening-Methoden unter Verwendung eines Strukturmodells von FIH
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
DK1644336T3 (da) 2003-06-06 2011-05-09 Fibrogen Inc Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
AU2005250412B2 (en) 2004-05-28 2009-09-17 Fibrogen, Inc. HIF prolyl hydroxylase activity assay
JP2008500951A (ja) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 二環化合物
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
BRPI0611670A2 (pt) 2005-06-15 2016-11-16 Fibrogen Inc método para o tratamento ou prevenção de câncer em um indivíduo
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
WO2007070359A2 (en) 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CN101400690A (zh) 2006-01-09 2009-04-01 英国技术集团国际有限公司 低氧诱导因子-1调节剂和相关用途
EP1983823A1 (en) 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
ES2922078T3 (es) * 2006-06-26 2022-09-07 Akebia Therapeutics Inc Inhibidores de prolil hidroxilasa y métodos de uso
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
CN101663037A (zh) 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
MX2009012000A (es) 2007-05-18 2009-11-19 Bayer Schering Pharma Ag Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
WO2009020119A1 (ja) 2007-08-06 2009-02-12 Senju Pharmaceutical Co., Ltd. ＨＩＦ－１αおよびＨＩＦ－２α発現阻害物質含有医薬
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
EA201000915A1 (ru) 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
CA2716706C (en) * 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
CA2719000A1 (en) * 2008-03-20 2009-09-24 Forest Laboratories Holdings Limited Piperidine derivatives as inhibitors of stearoyl-coa desaturase
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
ES2383273T3 (es) * 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
CA2736732A1 (en) 2008-09-15 2010-03-18 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
JP5638513B2 (ja) * 2009-03-31 2014-12-10 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途
KR101445946B1 (ko) 2009-11-06 2014-09-29 에르피오 세러퓨틱스 인코포레이티드 프롤릴 히드록실라아제 저해제
MX2013014310A (es) * 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
NO2686520T3 (OSRAM) * 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
WO2013013609A1 (en) 2011-07-22 2013-01-31 Zhejiang Beta Pharma Incorporation Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
KR102461176B1 (ko) 2013-06-13 2022-11-01 아케비아 테라퓨틱스 인코포레이티드 빈혈 치료용 조성물 및 치료방법
AU2014306496A1 (en) 2013-08-16 2016-03-03 Ohio State Innovation Foundation Compositions and methods for modulating DNA methylation
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CN106132201A (zh) 2014-01-23 2016-11-16 阿克比治疗有限公司 用于治疗眼部疾病的组合物和方法
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid

Also Published As

Publication number Publication date
SI2718265T1 (sl) 2016-03-31
EP3000808B1 (en) 2017-09-27
EP3683209A1 (en) 2020-07-22
HRP20151416T1 (hr) 2016-03-25
CY1117177T1 (el) 2017-04-05
JP7284309B2 (ja) 2023-05-30
RU2013158640A (ru) 2015-07-20
KR20140037192A (ko) 2014-03-26
CA3135440A1 (en) 2012-12-13
HUE057571T2 (hu) 2022-05-28
LT3290404T (lt) 2020-02-25
JP7685552B2 (ja) 2025-05-29
US9776969B2 (en) 2017-10-03
CN106518759B (zh) 2019-07-30
JP6510094B2 (ja) 2019-05-08
HUE034975T2 (en) 2018-05-02
KR102059366B1 (ko) 2019-12-26
DK2718265T3 (en) 2016-01-25
KR102293016B1 (ko) 2021-08-26
CY1122639T1 (el) 2021-03-12
PT3290404T (pt) 2020-02-19
NO2686520T3 (OSRAM) 2018-03-17
PL3683209T3 (pl) 2022-02-21
SI3000808T1 (en) 2018-02-28
CA2838194A1 (en) 2012-12-13
EP3290404B1 (en) 2019-12-11
AU2020204528B2 (en) 2022-07-14
MX347709B (es) 2017-05-10
AU2012268426A1 (en) 2014-01-09
PL3000808T3 (pl) 2018-03-30
SMT201600013B (it) 2016-02-25
KR20190031593A (ko) 2019-03-26
KR20200121911A (ko) 2020-10-26
SI3290404T1 (sl) 2020-03-31
ES2647602T3 (es) 2017-12-22
US20120309977A1 (en) 2012-12-06
RU2602083C2 (ru) 2016-11-10
US20190375713A1 (en) 2019-12-12
LT3683209T (lt) 2022-01-10
SI3683209T1 (sl) 2022-03-31
RU2016139352A3 (OSRAM) 2020-01-27
JP6290781B2 (ja) 2018-03-07
IL229775A (en) 2016-06-30
RS54517B1 (sr) 2016-06-30
JP2023103414A (ja) 2023-07-26
US20150361043A1 (en) 2015-12-17
WO2012170377A1 (en) 2012-12-13
KR102171315B1 (ko) 2020-10-28
HK1196616A1 (zh) 2014-12-19
DK3683209T3 (da) 2021-12-06
RU2764667C2 (ru) 2022-01-19
US10246416B2 (en) 2019-04-02
KR102032864B1 (ko) 2019-10-16
EP3000808A1 (en) 2016-03-30
RS56580B1 (sr) 2018-02-28
AU2012268426B2 (en) 2017-02-16
AU2020204528A1 (en) 2020-07-30
HK1252109A1 (en) 2019-05-17
JP2021059573A (ja) 2021-04-15
RS59902B1 (sr) 2020-03-31
US9145366B2 (en) 2015-09-29
AU2018250355A1 (en) 2018-11-08
PL2718265T3 (pl) 2016-04-29
HK1216173A1 (en) 2016-10-21
SMT202000061T1 (it) 2020-03-13
JP2018111697A (ja) 2018-07-19
EP3683209B1 (en) 2021-11-10
KR102000485B1 (ko) 2019-07-16
US20170362178A1 (en) 2017-12-21
HRP20211916T1 (hr) 2022-03-18
HUE026096T2 (en) 2016-05-30
ES2559850T3 (es) 2016-02-16
HRP20171740T1 (hr) 2018-03-09
PT2718265E (pt) 2016-02-15
JP2019123741A (ja) 2019-07-25
HRP20200197T1 (hr) 2020-05-15
EP3290404A1 (en) 2018-03-07
NZ618570A (en) 2015-07-31
KR20190032617A (ko) 2019-03-27
CA2838194C (en) 2022-01-11
AU2017202414B2 (en) 2018-07-19
PT3000808T (pt) 2017-11-23
PT3683209T (pt) 2021-12-15
KR20190141805A (ko) 2019-12-24
US20210122715A1 (en) 2021-04-29
SMT201700534T1 (it) 2018-01-11
ES2771232T3 (es) 2020-07-06
JP2022081597A (ja) 2022-05-31
HUE048044T2 (hu) 2020-05-28
EP4026829A1 (en) 2022-07-13
CN103717575A (zh) 2014-04-09
EP2718265A4 (en) 2014-11-19
CY1119605T1 (el) 2018-04-04
CN106518759A (zh) 2017-03-22
ES2900572T3 (es) 2022-03-17
DK3000808T3 (da) 2017-11-27
PL3290404T3 (pl) 2020-06-01
MX2013014228A (es) 2014-03-26
JP7039682B2 (ja) 2022-03-22
US11267785B2 (en) 2022-03-08
US20230002323A1 (en) 2023-01-05
AU2017202414A1 (en) 2017-05-04
MX337216B (es) 2016-02-18
AU2018250355B2 (en) 2020-04-09
US10738010B2 (en) 2020-08-11
LT3000808T (lt) 2018-01-25
RU2016139352A (ru) 2018-12-13
JP6816195B2 (ja) 2021-01-20
JP2014522409A (ja) 2014-09-04
CY1124874T1 (el) 2022-11-25
EP2718265A1 (en) 2014-04-16
EP2718265B1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
DK3290404T3 (da) 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrilderivater som intermediater til fremstillingen af [(5-(halophenyl)-3-hydroxypyridin-2-carbonyl)-amino]alkansyrederivater
DK2710018T3 (da) Makrocykliske forbindelser som proteinkinasehæmmere
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
DK2419429T3 (da) Imidazopyraziner som inhibitorer af proteinkinaser
SMT201600464B (it) Procedimento per la preparazione di esterolo
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
DK2729443T6 (da) Benzylaminderivater som inhibitorer af plasmakallikrein
PL3415531T3 (pl) Białka wiążące antygen
DK2771364T3 (da) Fremstilling af heterodimere proteiner
DK3321276T3 (da) Fusionsproteiner til behandling af metaboliske lidelser
DK3111764T3 (da) Tensider af amin-typen til styring af herbicid spraydrift
EP2793751A4 (en) PLATFORMS FOR MITRALKLAPPENERSATZ
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
EP2616024A4 (en) BALANCED PHAKOEMULSIFICATION TIP
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
DK3269802T3 (da) Forbindelser til forbedret virustransduktion
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
ES2603028T8 (es) Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
CO6900146A2 (es) Imidazopiridazinas sustituidas con amino
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
DK3103797T3 (da) 2,5-dioxoimidazolidin-1-yl-3-phenylurinstofderivater som formylpeptidreceptor-lignende-1- (fprl-1) receptormodulatorer
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
BR112013013028A2 (pt) processo para a preparação de derivados de carbamato de fenila